Table VI -.
Intervention studies with phytoestrogens and bone health in women including findings on bone markers.
| Reference | Subjects | Intervention (protein type and daily isoflavone level) | Study length | Findings Bone markers endpoints |
|---|---|---|---|---|
| Wong, 2000 | Postmenopausal n = 6 Open pilot study Mean age 55.4 y | Soy isoflavones 160 mg/d | 6 wk | Resorption markers: uDpy -7 ± 41%, Urinary Ca concentration -12 ± 46% s PTH +33 ± 60% Urinary Ca excretion -5 ± 29% Bone formation markers: sOC 9 ± 15% |
| Serum BAP -16 ± 23%, IGF-I -8 ± 27% Changes are of similar magnitude to those reported for ERT. | ||||
| Scheiber, 2001 | Postmenopausal n = 42 Mean age 55.5 y Open pilot study | Whole soy foods, 60 mg isoflavones/d No Ca supplementation | 3 mo | Resorption markers: serum ALP unchanged, urinary NTx decreased 13.9% Formation markers: serum OC increased 10.3%. |
| Lu et al., 2002 | Postmenopausal n = 12 Age range: 49-66 y | Soy milk 1.08 L/d ≈ 112 mg isoflavones | 4 mo | Increase in uDpy 21% and serum BAP 18%, increase in OC 34%. Values returned to prediet level 4 mo after diet. No estrogenic effects on uterus. No changes in serum levels of PTH, follicle-stimulating hormone or estradiol. |
Modified from Setchell KDR et al., 2003 (68).
BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; uDpy, urinary deoxypiridinoline; PTH. parathyroid hormone; BAP, bone-specific alkaline phosphatase; IGF-I, insulin-like growth factor; ERT, estrogen replacement therapy; NTx, crosslinked N-telopeptides of type I collagen; OC osteocalcin; Ca, calcium; ALP, alkaline phosphatase.